Abstract
The present invention pertains to: a pharmaceutical product comprising an (anti-HER3 antibody)-drug conjugate and a RASG12C inhibitor, and/or a treatment method characterized by administering a combination of an (anti-HER3 antibody)-drug conjugate and a RASG12C inhibitor to a subject.
Full Text
What is claimed is:
The present invention pertains to: a pharmaceutical product comprising an (anti-HER3 antibody)-drug conjugate and a RASG12C inhibitor, and/or a treatment method characterized by administering a combination of an (anti-HER3 antibody)-drug conjugate and a RASG12C inhibitor to a subject.
Timeline
Filed
03/02/2026Published
06/11/2026Granted
Not AvailableIPC Codes(3)
A61K 47/68:the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/519:ortho- or peri-condensed with heterocyclic rings
A61P 35/00:Antineoplastic agents